Announcements
- Matinas BioPharma Prices $10 Million Registered Direct Offering
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- Matinas BioPharma to Present at Biotech Showcase 2024
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
More ▼
Key statistics
On Thursday, Matinas BioPharma Holdings Inc (6LJ:DEU) closed at 0.172, 77.32% above the 52 week low of 0.097 set on Oct 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1716 |
---|---|
High | 0.178 |
Low | 0.139 |
Bid | 0.1662 |
Offer | 0.172 |
Previous close | 0.172 |
Average volume | 10.95k |
---|---|
Shares outstanding | 250.82m |
Free float | 244.48m |
P/E (TTM) | -- |
Market cap | 45.52m USD |
EPS (TTM) | -0.1056 USD |
Data delayed at least 15 minutes, as of Apr 25 2024.
More ▼